Home 
Today's Top Picks 
Top Performers 
Watchlist 
My Robo Portfolios 
ETF Zone 
Help & Tutorial 
Cancel anytime
- Chart
- Upturn Summary
- Highlights
- Valuation
- Analyst Ratings
Upturn AI SWOT - About
In8bio Inc (INAB)
- BUY Advisory
- SELL Advisory (Profit)
- SELL Advisory (Loss)
- Profit
- Loss
- Pass (Skip investing)
Stock price based on last close (see disclosures)
- ALL
- YEAR
- MONTH
- WEEK
Upturn Advisory Summary
04/01/2025: INAB (1-star) is currently NOT-A-BUY. Pass it for now.
Upturn Star Rating
Not Recommended Performance
These Stocks/ETFs, based on Upturn Advisory, consistently fall short of market performance, signaling caution before investing.
AI Based Fundamental Rating
Not Recommended Performance
These Stocks/ETFs, based on Upturn Advisory, consistently fall short of market performance, signaling caution before investing.
Analysis of Past Performance
Type Stock | Historic Profit -87.96% | Avg. Invested days 15 | Today’s Advisory PASS |
Upturn Star Rating | Upturn Advisory Performance  1.0 | Stock Returns Performance  1.0 |
| Profits based on simulation | Last Close 04/01/2025 |
Key Highlights
Company Size Small-Cap Stock | Market Capitalization 15.90M USD | Price to earnings Ratio - | 1Y Target Price 3.59 |
Price to earnings Ratio - | 1Y Target Price 3.59 | ||
Volume (30-day avg) 1539449 | Beta 0.03 | 52 Weeks Range 0.16 - 1.74 | Updated Date 04/1/2025 |
52 Weeks Range 0.16 - 1.74 | Updated Date 04/1/2025 | ||
Dividends yield (FY) - | Basic EPS (TTM) -0.48 |
Earnings Date
Report Date 2025-03-14 | When - | Estimate -0.08 | Actual -0.04 |
Profitability
Profit Margin - | Operating Margin (TTM) - |
Management Effectiveness
Return on Assets (TTM) -67.7% | Return on Equity (TTM) -154.44% |
Valuation
Trailing PE - | Forward PE - | Enterprise Value 7431458 | Price to Sales(TTM) - |
Enterprise Value 7431458 | Price to Sales(TTM) - | ||
Enterprise Value to Revenue - | Enterprise Value to EBITDA -1.15 | Shares Outstanding 81258800 | Shares Floating 53312249 |
Shares Outstanding 81258800 | Shares Floating 53312249 | ||
Percent Insiders 5.09 | Percent Institutions 36.95 |
Analyst Ratings
Rating 4 | Target Price 4.75 | Buy 2 | Strong Buy 1 |
Buy 2 | Strong Buy 1 | ||
Hold 1 | Sell - | Strong Sell - | |
Strong Sell - |
Upturn AI SWOT
In8bio Inc
Company Overview
History and Background
In8bio Inc. is a clinical-stage biopharmaceutical company focused on developing allogeneic gamma-delta T cell therapies for cancer. Founded in 2016, it has progressed through preclinical and early clinical trials, focusing on solid tumors and hematological malignancies.
Core Business Areas
- Gamma-Delta T Cell Therapy: Developing allogeneic gamma-delta T cell therapies to treat cancer. The company focuses on genetically modified and unmodified gamma-delta T cells targeting solid tumors and hematological malignancies.
Leadership and Structure
Jeffrey (Jeff) Hatfield serves as Chief Executive Officer. The company operates with a management team focused on research and development, clinical operations, and finance.
Top Products and Market Share
Key Offerings
- INB-400: An autologous genetically modified (iC9/CD19CAR) gamma-delta T cell therapy, designed to target diffuse large B-cell lymphoma. Currently in Phase 1 clinical trials. Competitors include companies developing CAR-T cell therapies for B-cell lymphomas, such as Gilead (KITE) and Novartis.
- INB-200/INB-100: Allogeneic, unmodified gamma-delta T cell therapies targeting solid tumors, particularly glioblastoma (GBM) and hematological malignancies. Currently in Phase 1 clinical trials. Competitors include companies developing cell therapies and immunotherapies for GBM, such as Northwest Biotherapeutics and Bristol Myers Squibb.
Market Dynamics
Industry Overview
The cell therapy market is rapidly growing, with significant investment and innovation in CAR-T cells, NK cells, and gamma-delta T cells. It is marked by intense competition, regulatory scrutiny, and high development costs.
Positioning
In8bio is positioned as a developer of allogeneic gamma-delta T cell therapies, which aim to offer advantages over traditional CAR-T cell therapies by being off-the-shelf and potentially safer. Their position is considered niche but with growth potential.
Total Addressable Market (TAM)
The total addressable market for cell therapies in oncology is estimated to reach billions of dollars, encompassing various hematological malignancies and solid tumors. In8bio is positioned to address a segment of this TAM, focusing on GBM and certain lymphomas.
Upturn SWOT Analysis
Strengths
- Novel gamma-delta T cell therapy platform
- Allogeneic approach potentially offers scalability and cost advantages
- Experienced management team
- Early clinical trial data showing promise
Weaknesses
- Clinical stage company with no approved products
- High cash burn rate
- Dependence on successful clinical trial outcomes
- Limited market validation compared to established CAR-T therapies
Opportunities
- Partnerships with larger pharmaceutical companies
- Expansion of pipeline to additional cancer indications
- Positive clinical trial results leading to accelerated regulatory pathways
- Advancements in cell therapy manufacturing and delivery technologies
Threats
- Clinical trial failures
- Competition from established CAR-T therapies and other immunotherapies
- Regulatory hurdles
- Financing risks
Competitors and Market Share
Key Competitors
- GILD
- NVS
- BMY
- NK
- ARWR
Competitive Landscape
In8bio competes with larger pharmaceutical companies and specialized cell therapy companies. Their gamma-delta T cell platform offers a differentiated approach, but faces challenges from established therapies.
Major Acquisitions
Growth Trajectory and Initiatives
Historical Growth: Growth is dependent on clinical trial progress and securing financing.
Future Projections: Future growth projections depend on successful clinical trials.
Recent Initiatives: Recent initiatives include advancing clinical trials.
Summary
In8bio is a clinical-stage company with a promising allogeneic gamma-delta T cell therapy platform. Its success hinges on the outcomes of its clinical trials, particularly for INB-400 and INB-200/INB-100. The company needs to manage its cash effectively and mitigate clinical and regulatory risks. The company should also look out for competitors entering the market and developing their own therapies.
Similar Companies
- GILD
- NVS
- BMY
- NK
- ARWR
Sources and Disclaimers
Data Sources:
- Company Website
- SEC Filings
- Analyst Reports
Disclaimers:
This analysis is for informational purposes only and does not constitute investment advice. Financial data may be incomplete or outdated. Market share estimates are approximate.
AI Summarization is directionally correct and might not be accurate.
Summarized information shown could be a few years old and not current.
Fundamental Rating based on AI could be based on old data.
AI-generated summaries may have inaccuracies (hallucinations). Please verify the information before taking action.
About In8bio Inc
Exchange NASDAQ | Headquaters New York, NY, United States | ||
IPO Launch date 2021-07-30 | Co-Founder, President, CEO & Director Mr. Tai-Wei Ho | ||
Sector Healthcare | Industry Biotechnology | Full time employees 18 | Website https://in8bio.com |
Full time employees 18 | Website https://in8bio.com | ||
IN8bio, Inc., a clinical-stage biopharmaceutical company, focuses on the discovery, development, and commercialization of gamma-delta T cell therapies for the treatment of solid and liquid tumors. Its lead product candidates include INB-400, which is in Phase 2 clinical trial to treat newly diagnosed glioblastoma (GBM); INB-200, a genetically modified autologous gamma-delta T cell product candidate that is in Phase I clinical trial for the treatment of GBM and other cancers; and INB-100, an allogeneic product candidate, which is in Phase I clinical trial to treat patients with hematologic malignancies undergoing hematopoietic stem cell transplantation. The company develops INB-300 and INB-500 that are in preclinical phase for treatment of acute myeloid leukemia, and other solid and hematological tumor types. The company was formerly known as Incysus Therapeutics, Inc. and changed its name to IN8bio, Inc. in August 2020. IN8bio, Inc. was incorporated in 2016 and is based in New York, New York.
Upturn is now on iOS and Android!
Experience Upturn on your mobile. Install it now!
Note: This website is maintained by Upturn Corporation, which is an investment adviser registered with the U.S. Securities and Exchange Commission. Such registration does not imply a certain level of skill or training. Investing in securities has risks. Past performance is no guarantee of future returns. No assurance is provided as to any particular investment return, and you may lose money using our services. You are strongly advised to consult appropriate counsel before making any investments in companies you learn about through our services. You should obtain appropriate legal, tax, investment, accounting, and other advice that takes into account your investment portfolio and overall financial situation. You are solely responsible for conducting due diligence on a potential investment. We do not affect trades for you. You will select your own broker through which to transact. Investments are not FDIC insured, they are not guaranteed, and they may lose value. Please see the Privacy Policy, Terms of Use, and Disclosure for more information.